• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

mBio. Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate

Giuseppe

Emeritus
[Source: mBio, full page: (LINK). Abstract, edited.]


Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate


Fernando Almaz?n<SUP>a</SUP>, Marta L. DeDiego<SUP>a</SUP>, Isabel Sola<SUP>a</SUP>, Sonia Zu?iga<SUP>a</SUP>, Jose L. Nieto-Torres<SUP>a</SUP>, Silvia Marquez-Jurado<SUP>a</SUP>, German Andr?s<SUP>b</SUP>, Luis Enjuanes<SUP>a</SUP>
<SUP></SUP>
Author Affiliations: Department of Molecular and Cell Biology, Centro Nacional de Biotecnolog?a (CNB-CSIC), Campus Universidad Aut?noma de Madrid, Cantoblanco, Madrid, Spain<SUP>a </SUP>Centro de Biolog?a Molecular Severo Ochoa (CBMSO-CSIC-UAM), Campus Universidad Aut?noma de Madrid, Cantoblanco, Madrid, Spain<SUP>b</SUP>
<SUP></SUP>
Address correspondence to Luis Enjuanes, L.Enjuanes@cnb.csic.es.

F.A. and M.L.D. contributed equally to this work.

Editor Michael Buchmeier, University of California, Irvine


ABSTRACT

Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging coronavirus infecting humans that is associated with acute pneumonia, occasional renal failure, and a high mortality rate and is considered a threat to public health. The construction of a full-length infectious cDNA clone of the MERS-CoV genome in a bacterial artificial chromosome is reported here, providing a reverse genetics system to study the molecular biology of the virus and to develop attenuated viruses as vaccine candidates. Following transfection with the cDNA clone, infectious virus was rescued in both Vero A66 and Huh-7 cells. Recombinant MERS-CoVs (rMERS-CoVs) lacking the accessory genes 3, 4a, 4b, and 5 were successfully rescued from cDNA clones with these genes deleted. The mutant viruses presented growth kinetics similar to those of the wild-type virus, indicating that accessory genes were not essential for MERS-CoV replication in cell cultures. In contrast, an engineered mutant virus lacking the structural E protein (rMERS-CoV-ΔE) was not successfully rescued, since viral infectivity was lost at early passages. Interestingly, the rMERS-CoV-ΔE genome replicated after cDNA clone was transfected into cells. The infectious virus was rescued and propagated in cells expressing the E protein in trans, indicating that this virus was replication competent and propagation defective. Therefore, the rMERS-CoV-ΔE mutant virus is potentially a safe and promising vaccine candidate to prevent MERS-CoV infection.


IMPORTANCE

Since the emergence of MERS-CoV in the Arabian Peninsula during the summer of 2012, it has already spread to 10 different countries, infecting around 94 persons and showing a mortality rate higher than 50%. This article describes the development of the first reverse genetics system for MERS-CoV, based on the construction of an infectious cDNA clone inserted into a bacterial artificial chromosome. Using this system, a collection of rMERS-CoV deletion mutants has been generated. Interestingly, one of the mutants with the E gene deleted was a replication-competent, propagation-defective virus that could only be grown in the laboratory by providing E protein in trans, whereas it would only survive a single virus infection cycle in vivo. This virus constitutes a vaccine candidate that may represent a balance between safety and efficacy for the induction of mucosal immunity, which is needed to prevent MERS-CoV infection.


Footnotes

Citation Almaz?n F, DeDiego ML, Sola I, Zu?iga S, Nieto-Torres JL, Marquez-Jurado S, Andr?s G, Enjuanes L. 2013. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio 4(5):e00650-13. doi:10.1128/mBio.00650-13.

Received 9 August 2013 Accepted 12 August 2013 Published 10 September 2013

Copyright ? 2013 Almaz?n et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported license, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.


-
-------
 
Back
Top Bottom